References
- AbdelkafiH, NayB. 2012. Natural products from Cephalotaxus sp.: chemical diversity and synthetic aspects. Nat Prod Rep.29:845–869.
- Cephalotaxus Research Coordinating Group. 1976. Cephalotaxus esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J.2:263–272.
- Chinese People's Liberation Army 187th Hospital. 1977. Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chin Med J.3:319–324.
- ChoiYH, YooK, KimJ. 2003. HPLC–electrospray ionization–MS–MS analysis of Cephalotaxus harringtonia leaves and enhancement of the extraction efficiency of alkaloids therein by SFE. J Chromatogr Sci.41:67–72.
- CisowskiW, MazolI, GleńskM. 2005. Investigation of the essential oils from three Cephalotaxus species. Acta Pol Pharm.62:461–463.
- Editorial Board of China Herbal. 1999. State Administration of Traditional Chinese Medicine, China, China HerbalVol. 4. Shanghai: Shanghai Science and Technology Press; p. 335.
- MoritaH, YoshinagaM, KobayashiJ. 2005. Cephalezomines G, H, J, K, L. and M, new alkaloids from Cephalotaxus harringtonia var. nana. Tetrahedron. 58:5489–5495.
- SaeedMK, DengY, DaiR. 2008. Attenuation of biochemical parameters in streptozotocin-induced diabetic rats by oral administration of extracts and fractions of Cephalotaxus sinensis. J Clin Biochem Nutr.42:21–28.
- ShankarU. 2008. Blooming potential of the detached shoots of Cephalotaxus griffithii Hook. f.Curr Sci.95:320–321.
- SpencerGF, PlattnerRD, PowellRG. 1976. Quantitative gas chromatography and gas chromatography–mass spectrometry of Cephalotaxus alkaloids. J Chromatogr.120:335–341.
- TakanoI, YasudaI, NishijimaM, HitotsuyanagiY, TakeyaK, ItokawaH. 1996. Drupangtonine, a novel antileukemic alkaloid from C. harringtonia var. drupacea. Bioorg Med Chem Lett.6:1689–1690.
- Yan-QingM, Meng-RuG, Tai-PingZ, Guang-EnM, Chun-ErL, HuaH, Yun-HuaY. 1984. The estimation of harringtonine and homoharringtonine of antileukemic alkaloids of C. fortunei Hook. f. and Cephalotaxus sinensis (Rehd. et Wils) Li. Acta Bot Sin. 26:405–410.
- YinS, WangR, ZhouF, ZhangH, JingY. 2011. Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells. Mol Pharmacol.79:1072–1083.